Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib + Bicalutamide in Asymptomatic mCRPC
NCT00659438Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Vandetanib + Bicalutamide with Placebo + Bicalutamide (2 arms). Primary endpoint: Prostate Specific Antigen Progression Free Rate at 4 months. Started Feb 2008; status: completed.
02
Drugs
vandetanib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00659438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659438.